Timothy F. Howe
Tim has been investing in private equity since joining the Schroder Ventures US operation in 1984. He went on to form Collinson Howe Venture Partners (“CHVP”) in 1990, and co-founded CHL Medical Partners in 1997. Tim has co-managed multiple venture capital portfolios, including multiple funds at Schroder Ventures and CHL Medical Partners, Biotechnology Investment Group LLC, HealthInvest Equity Partners, L.P., and CHVP’s portfolio.

Tim has been a lead investor in many start-up and early stage ventures in the biotechnology, medical device and services areas, including Incyte Pharmaceuticals (NASDAQ “INCY”), American Renal Associates (“ARA”), Alexion Pharmaceuticals, Inc. (ALXN), Ascend Health, Inc. (sold to UHS), Innotech, Inc. (IIII before sale to Johnson & Johnson), Camitro Corporation (sold to ArQule, Inc.), Medicus Insurance Holdings (sold to NORCAL Mutual), Genomic Health (GHDX acquired by Exact Sciences), and RxCentric, Inc. (sold to Allscripts, Inc.).

Tim has been a director of thirty companies, both public and private; he currently serves on the boards of Ambra Health, Genome Medical, Inc., and CareWell Urgent Care Centers of New England.

Tim is a graduate of Columbia College and the Columbia Graduate School of Business, where he was an Adjunct Assistant Professor teaching Venture Capital Management 1995 – 2012.

Tim can be reached at thowe@chlmedical.com and LinkedIn.